{
    "nctId": "NCT04941885",
    "briefTitle": "Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer",
    "officialTitle": "A Phase II Single-arm Clinical Trial of the Efficacy and Tolerability of Inetetamab Combined With Cyclophosphamide Metronomic Chemotherapy and Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 78,
    "primaryOutcomeMeasure": "Objective response rate (ORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form;\n2. 18-75 years old;\n3. The expected survival period is \u226512 weeks;\n4. Eastern Cooperative Oncology Group (ECOG) score \\[0-2\\] points;\n5. The diagnosis of invasive carcinoma by histology or cytology; Estrogen receptor (ER) positive (defined as \\>1% nuclear ER staining); HER2 negative (defined as IHC 0 or 1+, or HER2(2+) with HER2 FISH detection no amplification);\n6. Inoperable or recurrent/metastatic breast cancer patients with aromatase inhibitor treatment failure;\n7. In the state of disease progression before enrollment;\n8. Measurable disease according to RECIST version 1.1 or only bone metastasis;\n9. Adequate hematological, hepatic and renal function;\n10. NYHA class I or II and Left ventricular ejection fraction (LVEF) \u226550%.\n11. The diagnosis of invasive carcinoma by histology or cytology: Hormone receptor (HR) positive (defined as \\>1% nuclear estrogen receptor staining); HER2 positive (defined as IHC 3+, or HER2 FISH detection amplification);\n12. In the state of disease progression before enrollment;\n13. Have lesions able to and agree to perform tissue biopsy at the time requested in the study;\n14. Treatment \u22651 line after recurrence/metastasis, or relapse within 12 months after completing trastuzumab-based adjuvant therapy or during trastuzumab adjuvant therapy;\n15. Previously received trastuzumab for anti-HER2 therapy;\n16. Measurable disease according to RECIST version 1.1.\n\nExclusion Criteria:\n\n1. Allergic to the ingredients of Inetetamab, cyclophosphamide or similar drugs;\n2. Concomitant diseases/conditions that is not controllable, and any other major illness that, in the investigator's judgment, will substantially increase the risk associated with the patient's participation in this study;\n3. Patients who cannot accept drugs orally;\n4. Women who are pregnant or breastfeeding or planning to give birth;\n5. Patients with currently symptomatic brain or meningeal metastasis;\n6. History of other primary malignancy;\n7. Resistant to steroidal or nonsteroidal aromatase Inhibitor;\n8. Have used Inetetamab;\n9. Patients with life-threatening, symptomatic, metastatic visceral disease.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}